Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HRH2 | P25021 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4596486 | 1.00 | HRH3 (0.71) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Oxalic Acid SCHEMBL20509708 | 1.00 | HRH3 (0.71) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Oxalic Acid SCHEMBL20509707 | 1.00 | HRH3 (0.71) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Glycolic Acid SCHEMBL21809382 | 0.95 | HRH3 (0.67) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Glycolic Acid SCHEMBL21809383 | 0.95 | HRH3 (0.67) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| SCHEMBL4094659 | 0.95 | HRH3 (0.74) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| SCHEMBL4094656 | 0.95 | HRH3 (0.74) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Fumaric Acid SCHEMBL20511714 | 0.94 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Fumaric Acid SCHEMBL20511715 | 0.94 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 | |
| Fumaric Acid SCHEMBL20511712 | 0.94 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600315-B1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2023-09-06 | — | — | EP | claimed |
| US-11179329-B2 | Therapeutical use of H3-ligands | BIOPROJET PHARMA (FR) | 2021-11-23 | — | — | US | claimed |
| US-20200093738-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2020-03-26 | — | — | US | claimed |
| CN-110891570-A | Novel therapeutic uses of H3-ligands | 生物计划制药公司 | 2020-03-17 | — | — | CN | claimed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | claimed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | claimed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | claimed |
| EP-3600315-B1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-11179329-B2 | Therapeutical use of H3-ligands | BIOPROJET PHARMA (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200093738-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2020-03-26 | — | — | US | disclosed |
| CN-110891570-A | Novel therapeutic uses of H3-ligands | 生物计划制药公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-3600315-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET Pharma (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172432-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2018-09-27 | — | — | WO | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179329-B2 | Therapeutical use of H3-ligands | HRH3, FCER2, FCGR2A | HRH3 1/4885KDM4E 490/4885ALDH1A1 1449/4885 |
| US-20200093738-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | HRH3, HNRNPH3, HRH4 | HRH3 1/4885KDM4E 368/4885ALDH1A1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.